Minimally invasive surgery for gastric cancer using dual-port technique
Dual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomised Clinical Trial
NA · Nanfang Hospital, Southern Medical University · NCT05494086
This study is testing a new type of minimally invasive surgery for gastric cancer to see if it is safer and helps patients recover faster compared to traditional methods.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University (other) |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05494086 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and effectiveness of dual-port laparoscopic distal gastrectomy (DPLDG) as a treatment for gastric cancer. By utilizing advanced multi-channel ports, the procedure aims to reduce the number of incisions required compared to traditional laparoscopic methods, potentially leading to fewer complications and quicker recovery times. Patients diagnosed with gastric adenocarcinoma and meeting specific clinical criteria will undergo this innovative surgical approach. The study will assess postoperative outcomes and complications associated with this minimally invasive technique.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 with a diagnosis of gastric adenocarcinoma and specific clinical tumor stages.
Not a fit: Patients with a history of upper abdominal surgery or those requiring emergency treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved surgical outcomes and faster recovery for patients with gastric cancer.
How similar studies have performed: Other studies have shown promising results with similar minimally invasive techniques, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. patients within 18--75 years old; 2. patients with a preoperative pathological diagnosis of gastric adenocarcinoma; 3. patients with a clinical tumor stage of T1N1,T2N0 according to the preoperative examinations (gastroscopy, ultrasound gastroscopy and computed tomography); 4. patients with a plan to undergo laparoscopic distal gastrectomy and obtain R0 surgical results; 5. patients without severe heart, liver, lung, or kidney dysfunction; 6. patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1; and (7) patients with American Society of Anesthesiologists (ASA) I-II. Exclusion Criteria: 1. patients with a history of upperabdominal surgery; 2. patients who presentedas an emergency case; 3. patients with other histories of malignant diseases within 5 years; 4. patients with prior neoadjuvant chemotherapy or radiation therapy; and (5)patients who need simultaneous surgical treatment for other malignant diseases.
Where this trial is running
Guangzhou, Guangdong
- Nanfang Hospital — Guangzhou, Guangdong, China (RECRUITING)
Study contacts
- Principal investigator: Guoxin Li, Ph.D — Nanfang Hospital, Southern Medical University
- Study coordinator: Xinhua Chen, Ph.D
- Email: xinhuachen@163.com
- Phone: 8615626452302
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Gastric Cancer